Delving into the Latest Updates on SI-F019 with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms

Recombinant human ACE2 fusion protein - Sichuan Baili Pharmaceutical

+ [2]

Target

Ang II x SARS-CoV-2 S protein

Mechanism

Ang II antagonists(Angiotensin II antagonists), SARS-CoV-2 S protein inhibitors(Coronavirus spike glycoprotein inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication

COVID-19Pulmonary Arterial HypertensionRespiratory Distress Syndrome

Inactive Indication-

Originator Organization

Sichuan Biokin Pharmaceutical Co., Ltd.

Active Organization

Sichuan Biokin Pharmaceutical Co., Ltd.

Inactive Organization

Sichuan Baili Pharmaceuticals Co.,Ltd

Systimmune, Inc.Startup

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Gene Sequence

Sequence Code 1044828046

Sequence Code 253341713

The purpose of this study is to determine if the IBD patient doing home monitoring by web app's for disease activity (DA) and fecal calprotectin (FC) on demand (OD), compared with patients doing home monitoring scheduled interval combined with "on demand"(SI+OD) ( every 3.month).
Will home monitoring of DA and FC OD vs SI+OD reduce frequency of relapse in one year follow up? Is the frequent FC measurement in SI+OD test group predictive of an early recognition of relapse, and thus help change the naturel course of disease? Will home monitoring of DA and FC in OD vs SI+OD change the course of the disease in terms of disease activity, spread of the disease, hospitalizations and number of hospitalization days, required surgery and outpatient visits? Is there a difference in patients' compliance with treatment plan between OD vs SI+OD ? Is there difference in patients-adherence between OD vs SI+OD ?

Start Date01 Jul 2015

Sponsor / Collaborator-

100 Clinical Results associated with SI-F019

Login to view more data

100 Translational Medicine associated with SI-F019

Login to view more data

100 Patents (Medical) associated with SI-F019

Login to view more data

33

Literatures (Medical) associated with SI-F019

01 Sep 2024·Food Research International

Exploring the potential of red pitaya pulp (Hylocererus sp.) as a plant-based matrix for probiotic delivery and effects on betacyanin content and flavoromics

Article

Author: Frohme, Marcus ; Saad, Susana Marta Isay ; Cucick, Ana Clara Candelaria ; Brödel, Oliver ; Suzuki, Juliana Yumi ; Herkenhoff, Marcos Edgar

This study evaluated the potential of red pitaya pulp fermented with Lacticaseibacillus paracasei subsp. paracasei F-19 (F-19) as a base for probiotic products. Physicochemical parameters, sugar, betacyanin, and phenolic contents, and antioxidant activity were analyzed over 28 days at 4 °C and compared to a non-fermented pulp, and to a pulp fermented with Bifidobacterium animalis subsp. lactis BB-12 (BB-12). Volatile compounds were identified using HS-SPME/GC-MS. Probiotic viability during storage and survival through in vitro-simulated gastrointestinal tract (GIT) stress were assessed. Red pitaya pulp, rich in moisture (85.83 g/100 g), carbohydrates (11.65 g/100 g), and fibers (2.49 g/100 g), supported fermentation by both strains. F-19 and BB-12 lowered pH, with F-19 showing stronger acidification, and maintained high viability (8.85-8.90 log CFU/mL). Fermentation altered sugar profiles and produced unique volatile compounds, enhancing aroma and sensory attributes. F-19 generated 2-phenylethanol, a unique flavor compound, absent in BB-12. Phenolic content initially increased but antioxidant activity decreased during storage. Betacyanin remained stable for up to 14 days. Red pitaya improved F-19 viability through the simulated GIT, while BB-12 populations significantly decreased (p < 0.05). These results suggest red pitaya pulp is a promising plant-based matrix for F-19, offering protection during digestion and highlighting its potential as a functional food with enhanced bioactive compound bioavailability and sensory attributes.

13 Dec 2023·Journal of Agricultural and Food Chemistry

Synthesis, X-ray Crystal Structure, and Antimicrobial Studies of New Quinazolin-4(3H)-one Derivatives Containing the 1,2,4-Triazolo[3,4-b][1,3,4]thiadiazole Moiety and 4-Piperidinyl Linker

Article

Author: Yi, Mingyan ; An, Lian ; Wu, Nan ; Liu, Songsong ; Yan, Taisen ; Bao, Xiaoping ; Yang, Yehui ; Tian, Guangmin

A total of 35 new quinazolinone derivatives bearing the 1,2,4-triazolo[3,4-b][1,3,4]thiadiazole scaffold and the 4-piperidinyl linker were designed, prepared, and assessed for their antibacterial and antifungal activities. Among these derivatives, the chemical structure of compound F5 was clearly verified via single-crystal X-ray diffraction analysis. The experimental results revealed that some of the compounds displayed good even excellent inhibitory effects toward the tested phytopathogenic bacteria. For instance, compound F33 was capable of strongly inhibiting Xanthomonas oryzae pv. oryzae (Xoo) in vitro with an EC₅₀ (half-maximal effective concentration) value of 4.1 μg/mL, about 16-fold more effective than the commercialized bactericide bismerthiazol. Significantly, this compound also effectively suppressed the proliferation of Xoo in the potted rice plants, showing a good in vivo protection efficacy of 47.6% at 200 μg/mL. Subsequently, the antibacterial mechanisms of compound F33 were explored by means of different biophysical and biochemical methods. Last, some of the compounds were found to possess relatively good antifungal activities in vitro, like compound F19 against Phytophthora nicotianae (with an inhibition rate of 67.2% at 50 μg/mL). In a word, the current experimental results imply that the 4-piperidinyl-bridged quinazolinone-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole derivatives possess potential as lead compounds for developing more efficient anti-Xoo bactericides.

15 Aug 2023·Pharmaceuticals (Basel, Switzerland)

Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016-2022).

Review

Author: Zahid, Wajeeha ; Shabir, Ghulam ; Muneeba ; Saeed, Aamer ; Riaz, Zainab ; Naseer, Fatima ; Albericio, Fernando ; Khalil, Nafeesa

Fluorine is characterized by high electronegativity and small atomic size, which provide this molecule with the unique property of augmenting the potency, selectivity, metabolic stability, and pharmacokinetics of drugs. Fluorine (F) substitution has been extensively explored in drug research as a means of improving biological activity and enhancing chemical or metabolic stability. Selective F substitution onto a therapeutic or diagnostic drug candidate can enhance several pharmacokinetic and physicochemical properties such as metabolic stability and membrane permeation. The increased binding ability of fluorinated drug target proteins has also been reported in some cases. An emerging line of research on F substitution has been addressed by using ¹⁸F as a radiolabel tracer atom in the extremely sensitive methodology of positron emission tomography (PET) imaging. This review aims to report on the fluorinated drugs approved by the US Food and Drug Administration (FDA) from 2016 to 2022. It cites selected examples from a variety of therapeutic and diagnostic drugs. FDA-approved drugs in this period have a variety of heterocyclic cores, including pyrrole, pyrazole, imidazole, triazole, pyridine, pyridone, pyridazine, pyrazine, pyrimidine, triazine, purine, indole, benzimidazole, isoquinoline, and quinoline appended with either F-18 or F-19. Some fluorinated oligonucleotides were also authorized by the FDA between 2019 and 2022.

100 Deals associated with SI-F019

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	CN	Sichuan Biokin Pharmaceutical Co., Ltd.	05 Jul 2022
Pulmonary Arterial Hypertension	Phase 2	CN	Sichuan Biokin Pharmaceutical Co., Ltd.	05 Jul 2022
Respiratory Distress Syndrome	Phase 2	CN	Sichuan Biokin Pharmaceutical Co., Ltd.	05 Jul 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Pubmed \| Pediatr Infect Dis J	Not Applicable	-	-	Palivizumab (Immunocompromised children)	szttknbfhv(yubpresyrx): HR = 1.7 (95% CI, 0.9 - 3.4), P-Value = 0.118	-	01 Jun 2020
				Palivizumab (CMD)